Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein

The development of inhibitors toward factor VIII (FVIII) is a common and serious complication of hemophilia A (HA) therapy. Patients with hemophilia who develop inhibitors often undergo time‐ and resource‐intensive immune tolerance induction (ITI) protocols. We report a 15‐month‐old male with severe...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2016-05, Vol.63 (5), p.922-924
Main Authors: Groomes, Charles L., Gianferante, David M., Crouch, Gary D., Parekh, Dina S., Scott, David W., Lieuw, Kenneth
Format: Article
Language:English
Subjects:
Blood Coagulation Factor Inhibitors - immunology
Desensitization, Immunologic
eloctate
Factor VIII - administration & dosage
Factor VIII - antagonists & inhibitors
Factor VIII - genetics
Factor VIII - immunology
factor VIII inhibitors
Hematology
Hemophilia
hemophilia A
Hemophilia A - drug therapy
Hemophilia A - immunology
Humans
Immune Tolerance - drug effects
immune tolerance induction
Infant
Male
Oncology
Pediatrics
Receptors, Fc - administration & dosage
Receptors, Fc - genetics
Receptors, Fc - immunology
recombinant factor VIII-Fc fusion protein
Recombinant Fusion Proteins - administration & dosage
Recombinant Fusion Proteins - genetics
Recombinant Fusion Proteins - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of inhibitors toward factor VIII (FVIII) is a common and serious complication of hemophilia A (HA) therapy. Patients with hemophilia who develop inhibitors often undergo time‐ and resource‐intensive immune tolerance induction (ITI) protocols. We report a 15‐month‐old male with severe HA and a high‐titer inhibitor that occurred while receiving prophylactic treatment with recombinant FVIII (rFVIII), in whom significant inhibitor titer reduction was achieved with thrice weekly infusions of a new, prolonged half‐life rFVIII‐Fc fusion protein product (trade name Eloctate). Further studies are warranted to explore the potential of Eloctate in ITI protocols.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.25874